MAPS Act
Official title: To improve coordination of Federal efforts to identify and mitigate health and national security risks through maintaining a list of essential medicines, condu… Show full official titleShow less
Official title: To improve coordination of Federal efforts to identify and mitigate health and national security risks through maintaining a list of essential medicines, conducting a risk assessment of essential medicine supply chains, and creating a monitoring system to map essential medicine supply chains using data analytics.
More subjectsShow fewer subjects
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Referred to the House Committee on Energy and Commerce.
Mapping America’s Pharmaceutical Supply Act or the MAPS Act
This bill requires the Food and Drug Administration (FDA) to continually update its essential medicines list and identify risks and vulnerabilities in the associated supply chains.
In 2020, in response to an executive order, the FDA published a list of essential medicines deemed medically necessary to have available at all times. The bill requires the FDA to update and maintain this list to include drugs and ingredients (1) related to responding to public health threats and emergency incidents, (2) that are of greatest priority for providing health care and are at high risk of shortage, and (3) the shortage of which would adversely affect patients with chronic conditions. The FDA must review the list at least every two years and update it as appropriate.
Also, the bill requires the FDA to conduct a risk assessment of the supply chains for drugs and ingredients on the list and annually report its findings to Congress. The assessment must include information about key manufacturing materials, drugs with primarily foreign or single suppliers, manufacturing capacity, relevant public health and national security risks, and risk mitigation strategies.
Additionally, the Department of Health and Human Services (HHS) must map and monitor relevant supply chains to identify vulnerabilities and provide an annual status report to Congress. HHS must facilitate the secure exchange of information among agencies regarding locations and quantities of production and relevant regulatory actions.
- Introduced in House Formatted Text PDF Formatted XML
- THE UNITED STATES PHARMACOPEIAL CONVENTION
- VIZIENT, INC.
- PHLOW CORPORATION
- TIBER CREEK GROUP
- ASSOCIATION FOR ACCESSIBLE MEDICINES
- ASSOCIATION FOR CLINICAL ONCOLOGY
Bodies those filers lobbied
- HOUSE OF REPRESENTATIVES
- SENATE
- Health & Human Services, Dept of (HHS)
- Centers For Medicare and Medicaid Services (CMS)
- Commerce, Dept of (DOC)
- Defense, Dept of (DOD)
- Natl Economic Council (NEC)
- Office of Management & Budget (OMB)
Cite this page
U.S. Congress. (2026). H.R. 4191: MAPS Act. 119th Congress. Open America. https://openamerica.io/bill/119-HR-4191/
"H.R. 4191: MAPS Act." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-HR-4191/.
H.R. 4191, 119th Cong. (2026), https://openamerica.io/bill/119-HR-4191/.
[H.R. 4191: MAPS Act](https://openamerica.io/bill/119-HR-4191/)